View ValuationeChannelling 将来の成長Future 基準チェック /06現在、 eChannellingの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare Services 収益成長32.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 28eChannelling PLC, Annual General Meeting, Jun 19, 2026eChannelling PLC, Annual General Meeting, Jun 19, 2026, at 12:30 Sri Lanka Standard Time. Location: mobitel (pvt.) ltd., lesley ranagala mawatha, baseline road., Sri LankaNew Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.2% per year over the past 5 years. Revenue is less than US$1m (LK₨315m revenue, or US$945k). Market cap is less than US$10m (LK₨1.98b market cap, or US$5.93m). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change).Reported Earnings • May 16First quarter 2026 earnings released: EPS: LK₨0.17 (vs LK₨0.083 in 1Q 2025)First quarter 2026 results: EPS: LK₨0.17 (up from LK₨0.083 in 1Q 2025). Revenue: LK₨86.5m (up 29% from 1Q 2025). Net income: LK₨20.2m (up 115% from 1Q 2025). Profit margin: 23% (up from 14% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.New Risk • Nov 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Sri Lankan stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 3.6% per year over the past 5 years. High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m (LK₨277m revenue, or US$901k). Market cap is less than US$10m (LK₨1.97b market cap, or US$6.39m).Reported Earnings • Nov 17Third quarter 2025 earnings released: EPS: LK₨0.11 (vs LK₨0.05 in 3Q 2024)Third quarter 2025 results: EPS: LK₨0.11 (up from LK₨0.05 in 3Q 2024). Revenue: LK₨78.0m (up 20% from 3Q 2024). Net income: LK₨13.0m (up 129% from 3Q 2024). Profit margin: 17% (up from 8.7% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.New Risk • Aug 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (LK₨264m revenue, or US$875k). Market cap is less than US$10m (LK₨2.16b market cap, or US$7.16m). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change).Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 16%After last week's 16% share price gain to LK₨15.10, the stock trades at a trailing P/E ratio of 57.3x. Average trailing P/E is 33x in the Healthcare Services industry in Asia. Total returns to shareholders of 37% over the past three years.Reported Earnings • Aug 13Second quarter 2025 earnings released: EPS: LK₨0.05 (vs LK₨0.04 in 2Q 2024)Second quarter 2025 results: EPS: LK₨0.05 (up from LK₨0.04 in 2Q 2024). Revenue: LK₨66.2m (up 11% from 2Q 2024). Net income: LK₨6.70m (up 22% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (27% accrual ratio). Revenue is less than US$1m (LK₨258m revenue, or US$858k). Market cap is less than US$10m (LK₨1.71b market cap, or US$5.69m). Minor Risk Share price has been volatile over the past 3 months (6.4% average weekly change).お知らせ • Jun 02eChannelling PLC, Annual General Meeting, Jun 26, 2025eChannelling PLC, Annual General Meeting, Jun 26, 2025, at 12:30 Sri Lanka Standard Time. Location: new wing hall, sri lanka foundation institute, no.100, sri lanka padanam mawatha, independence, square, colombo 07, colombo Sri LankaReported Earnings • May 09First quarter 2025 earnings released: EPS: LK₨0.09 (vs LK₨0.09 in 1Q 2024)First quarter 2025 results: EPS: LK₨0.09 (in line with 1Q 2024). Revenue: LK₨66.9m (up 3.0% from 1Q 2024). Net income: LK₨11.4m (up 9.3% from 1Q 2024). Profit margin: 17% (up from 16% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.Board Change • Apr 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non Executive Director T.M.Ruwanthi Perera was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 01Full year 2024 earnings released: EPS: LK₨0.26 (vs LK₨0.36 in FY 2023)Full year 2024 results: EPS: LK₨0.26 (down from LK₨0.36 in FY 2023). Revenue: LK₨255.9m (down 5.6% from FY 2023). Net income: LK₨31.9m (down 27% from FY 2023). Profit margin: 13% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.お知らせ • Feb 08eChannelling PLC Appoints Suneth Haputhanthri as Independent, Non-Executive DirectoreChannelling PLC announced the appointment of Mr. Suneth Haputhanthri as independent, non-executive director. Effective date is 7 February 2025.Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: LK₨0.05 (vs LK₨0.09 in 3Q 2023)Third quarter 2024 results: EPS: LK₨0.05 (down from LK₨0.09 in 3Q 2023). Revenue: LK₨65.1m (down 5.4% from 3Q 2023). Net income: LK₨5.69m (down 50% from 3Q 2023). Profit margin: 8.7% (down from 17% in 3Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to LK₨15.00, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 28x in the Healthcare Services industry in Asia. Total returns to shareholders of 76% over the past three years.Buy Or Sell Opportunity • Oct 14Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 3.0% to LK₨13.70. The fair value is estimated to be LK₨11.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 6.2%.Buy Or Sell Opportunity • Sep 26Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 3.7% to LK₨14.00. The fair value is estimated to be LK₨11.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 6.2%.Reported Earnings • Jul 30Second quarter 2024 earnings released: EPS: LK₨0.04 (vs LK₨0.08 in 2Q 2023)Second quarter 2024 results: EPS: LK₨0.04 (down from LK₨0.08 in 2Q 2023). Revenue: LK₨59.8m (down 6.3% from 2Q 2023). Net income: LK₨5.49m (down 46% from 2Q 2023). Profit margin: 9.2% (down from 16% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.Reported Earnings • May 17First quarter 2024 earnings released: EPS: LK₨0.09 (vs LK₨0.082 in 1Q 2023)First quarter 2024 results: EPS: LK₨0.09 (up from LK₨0.082 in 1Q 2023). Revenue: LK₨65.0m (down 2.0% from 1Q 2023). Net income: LK₨10.4m (flat on 1Q 2023). Profit margin: 16% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.お知らせ • Apr 21eChannelling PLC, Annual General Meeting, May 14, 2024eChannelling PLC, Annual General Meeting, May 14, 2024, at 12:30 Sri Lanka Standard Time. Location: "Ruby",Bandaranaike Memorial International Conference Hall (BMICH) Bauddhaloka Mawatha Colombo Sri Lanka Agenda: To consider the Statement of Accounts of the company for the year ended 31 December 2023; to consider election of directors; to consider reappointment of Messrs KPMG, Chartered Accountants as auditors and to determine their remuneration; to authorize the Directors to determine their remuneration; and to consider other business matters.Reported Earnings • Mar 03Full year 2023 earnings released: EPS: LK₨0.36 (vs LK₨0.54 in FY 2022)Full year 2023 results: EPS: LK₨0.36 (down from LK₨0.54 in FY 2022). Revenue: LK₨271.2m (up 22% from FY 2022). Net income: LK₨43.8m (down 33% from FY 2022). Profit margin: 16% (down from 30% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 16Third quarter 2023 earnings released: EPS: LK₨0.09 (vs LK₨0.13 in 3Q 2022)Third quarter 2023 results: EPS: LK₨0.09 (down from LK₨0.13 in 3Q 2022). Revenue: LK₨68.7m (up 43% from 3Q 2022). Net income: LK₨11.4m (down 27% from 3Q 2022). Profit margin: 17% (down from 33% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to LK₨16.50, the stock trades at a trailing P/E ratio of 36.3x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 123% over the past three years.Reported Earnings • Aug 05Second quarter 2023 earnings released: EPS: LK₨0.08 (vs LK₨0.09 in 2Q 2022)Second quarter 2023 results: EPS: LK₨0.08 (down from LK₨0.09 in 2Q 2022). Revenue: LK₨63.9m (up 47% from 2Q 2022). Net income: LK₨10.2m (down 11% from 2Q 2022). Profit margin: 16% (down from 26% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to LK₨16.80, the stock trades at a trailing P/E ratio of 37x. Average trailing P/E is 36x in the Healthcare Services industry in Asia. Total returns to shareholders of 265% over the past three years.Reported Earnings • Apr 22Full year 2022 earnings released: EPS: LK₨0.54 (vs LK₨0.44 in FY 2021)Full year 2022 results: EPS: LK₨0.54 (up from LK₨0.44 in FY 2021). Revenue: LK₨221.5m (up 15% from FY 2021). Net income: LK₨65.5m (up 23% from FY 2021). Profit margin: 30% (up from 28% in FY 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 19%After last week's 19% share price gain to LK₨18.80, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 43x in the Healthcare Services industry in Asia. Total returns to shareholders of 437% over the past three years.Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to LK₨14.00, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 40x in the Healthcare Services industry in Asia. Total returns to shareholders of 300% over the past three years.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Independent Non Executive Chairman Anthony Rohan Fernando was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 23% share price gain to LK₨13.80, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 151% over the past three years.Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improved over the past weekAfter last week's 17% share price gain to LK₨11.60, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 40x in the Healthcare Services industry in Asia. Total returns to shareholders of 111% over the past three years.Reported Earnings • Nov 11Third quarter 2022 earnings released: EPS: LK₨0.13 (vs LK₨0.13 in 3Q 2021)Third quarter 2022 results: EPS: LK₨0.13 (in line with 3Q 2021). Revenue: LK₨48.0m (up 2.5% from 3Q 2021). Net income: LK₨15.7m (down 4.0% from 3Q 2021). Profit margin: 33% (down from 35% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improved over the past weekAfter last week's 24% share price gain to LK₨11.20, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 35x in the Healthcare Services industry in Asia. Total returns to shareholders of 115% over the past three years.Reported Earnings • Aug 09Second quarter 2022 earnings released: EPS: LK₨0.09 (vs LK₨0.06 in 2Q 2021)Second quarter 2022 results: EPS: LK₨0.09 (up from LK₨0.06 in 2Q 2021). Revenue: LK₨43.4m (up 18% from 2Q 2021). Net income: LK₨11.4m (up 65% from 2Q 2021). Profit margin: 26% (up from 19% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 21% share price gain to LK₨8.70, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 43x in the Healthcare Services industry in Asia. Total returns to shareholders of 71% over the past three years.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to LK₨6.90, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 41x in the Healthcare Services industry in Asia. Total returns to shareholders of 47% over the past three years.Valuation Update With 7 Day Price Move • May 30Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to LK₨7.00, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 36x in the Healthcare Services industry in Asia. Total returns to shareholders of 133% over the past three years.Reported Earnings • May 16First quarter 2022 earnings released: EPS: LK₨0.16 (vs LK₨0.16 in 1Q 2021)First quarter 2022 results: EPS: LK₨0.16 (vs LK₨0.16 in 1Q 2021). Revenue: LK₨59.5m (up 17% from 1Q 2021). Net income: LK₨19.2m (down 1.5% from 1Q 2021). Profit margin: 32% (down from 38% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorated over the past weekAfter last week's 27% share price decline to LK₨7.50, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 41x in the Healthcare Services industry in Asia. Total returns to shareholders of 74% over the past three years.Buying Opportunity • Mar 29Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 71%. The fair value is estimated to be LK₨10.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% per annum over the last 3 years. Earnings per share has grown by 29% per annum over the last 3 years.Valuation Update With 7 Day Price Move • Mar 17Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to LK₨10.30, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 158% over the past three years.Reported Earnings • Mar 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: LK₨0.44 (up from LK₨0.25 in FY 2020). Revenue: LK₨193.2m (up 49% from FY 2020). Net income: LK₨53.4m (up 78% from FY 2020). Profit margin: 28% (up from 23% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to LK₨12.40, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 202% over the past three years.Valuation Update With 7 Day Price Move • Feb 10Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to LK₨17.10, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 42x in the Healthcare Services industry in Asia. Total returns to shareholders of 307% over the past three years.Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to LK₨22.60, the stock trades at a trailing P/E ratio of 52.1x. Average trailing P/E is 49x in the Healthcare Services industry in Asia. Total returns to shareholders of 381% over the past three years.Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 23% share price gain to LK₨21.30, the stock trades at a trailing P/E ratio of 49.1x. Average trailing P/E is 52x in the Healthcare Services industry in Asia. Total returns to shareholders of 384% over the past three years.Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to LK₨11.20, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 44x in the Healthcare Services industry in Asia. Total returns to shareholders of 149% over the past three years.Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS LK₨0.13 (vs LK₨0.11 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: LK₨46.8m (up 17% from 3Q 2020). Net income: LK₨16.4m (up 19% from 3Q 2020). Profit margin: 35% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Sep 02Investor sentiment improved over the past weekAfter last week's 24% share price gain to LK₨8.40, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 53x in the Healthcare Services industry in Asia. Total returns to shareholders of 79% over the past three years.Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS LK₨0.06 (vs LK₨0.02 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: LK₨36.7m (up 60% from 2Q 2020). Net income: LK₨6.90m (up 144% from 2Q 2020). Profit margin: 19% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to LK₨7.00, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 55x in the Healthcare Services industry in Asia. Total returns to shareholders of 49% over the past three years.Reported Earnings • May 17First quarter 2021 earnings released: EPS LK₨0.16 (vs LK₨0.03 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: LK₨50.8m (up 56% from 1Q 2020). Net income: LK₨19.5m (up LK₨16.4m from 1Q 2020). Profit margin: 38% (up from 9.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 25New 90-day low: LK₨5.80The company is down 15% from its price of LK₨6.80 on 27 November 2020. The Sri Lankan market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 7.0% over the same period.Reported Earnings • Feb 25Full year 2020 earnings released: EPS LK₨0.25 (vs LK₨0.12 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: LK₨130.1m (flat on FY 2019). Net income: LK₨30.0m (up 100% from FY 2019). Profit margin: 23% (up from 12% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 02New 90-day low: LK₨6.10The company is down 14% from its price of LK₨7.10 on 04 November 2020. The Sri Lankan market is up 49% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 16% over the same period.Reported Earnings • Nov 04Third quarter 2020 earnings released: EPS LK₨0.11The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: LK₨40.1m (up 26% from 3Q 2019). Net income: LK₨13.7m (up 244% from 3Q 2019). Profit margin: 34% (up from 13% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Sep 24New 90-day high: LK₨6.00The company is up 40% from its price of LK₨4.30 on 26 June 2020. The Sri Lankan market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、eChannelling は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測COSE:ECL.N0000 - アナリストの将来予測と過去の財務データ ( )LKR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202631547122129N/A12/31/2025296384148N/A9/30/202527741-48-42N/A6/30/2025264344952N/A3/31/202525833-6-4N/A12/31/202425632-5-1N/A9/30/2024262345255N/A6/30/202426639126130N/A3/31/202427044-37-32N/A12/31/20232714414N/A9/30/202326951-19-14N/A6/30/202324955-191-186N/A3/31/2023228571624N/A12/31/202222266-64-54N/A9/30/202221057-42-32N/A6/30/2022209581524N/A3/31/2022202531318N/A12/31/2021193536467N/A9/30/2021169535961N/A6/30/2021162506873N/A3/31/2021148461723N/A12/31/202013030210N/A9/30/2020127191324N/A6/30/20201199513N/A3/31/2020128103547N/A12/31/201913015N/A24N/A9/30/201913126N/A4N/A6/30/201913229N/A15N/A3/31/201913332N/A-6N/A12/31/201813334N/A80N/A9/30/201813431N/A27N/A6/30/201813736N/A-8N/A3/31/201813734N/A6N/A12/31/201713636N/A-17N/A9/30/201711024N/A-15N/A6/30/201711428N/A-4N/A3/31/201712738N/AN/AN/A12/31/201614437N/A14N/A9/30/201618666N/A70N/A6/30/201620673N/A64N/A3/31/201621179N/A67N/A12/31/201521163N/A89N/A9/30/201517145N/A56N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ECL.N0000の予測収益成長が 貯蓄率 ( 4.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ECL.N0000の収益がLK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ECL.N0000の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ECL.N0000の収益がLK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ECL.N0000の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ECL.N0000の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 23:29終値2026/07/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋eChannelling PLC 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 28eChannelling PLC, Annual General Meeting, Jun 19, 2026eChannelling PLC, Annual General Meeting, Jun 19, 2026, at 12:30 Sri Lanka Standard Time. Location: mobitel (pvt.) ltd., lesley ranagala mawatha, baseline road., Sri Lanka
New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.2% per year over the past 5 years. Revenue is less than US$1m (LK₨315m revenue, or US$945k). Market cap is less than US$10m (LK₨1.98b market cap, or US$5.93m). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change).
Reported Earnings • May 16First quarter 2026 earnings released: EPS: LK₨0.17 (vs LK₨0.083 in 1Q 2025)First quarter 2026 results: EPS: LK₨0.17 (up from LK₨0.083 in 1Q 2025). Revenue: LK₨86.5m (up 29% from 1Q 2025). Net income: LK₨20.2m (up 115% from 1Q 2025). Profit margin: 23% (up from 14% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
New Risk • Nov 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Sri Lankan stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 3.6% per year over the past 5 years. High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m (LK₨277m revenue, or US$901k). Market cap is less than US$10m (LK₨1.97b market cap, or US$6.39m).
Reported Earnings • Nov 17Third quarter 2025 earnings released: EPS: LK₨0.11 (vs LK₨0.05 in 3Q 2024)Third quarter 2025 results: EPS: LK₨0.11 (up from LK₨0.05 in 3Q 2024). Revenue: LK₨78.0m (up 20% from 3Q 2024). Net income: LK₨13.0m (up 129% from 3Q 2024). Profit margin: 17% (up from 8.7% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
New Risk • Aug 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (LK₨264m revenue, or US$875k). Market cap is less than US$10m (LK₨2.16b market cap, or US$7.16m). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change).
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 16%After last week's 16% share price gain to LK₨15.10, the stock trades at a trailing P/E ratio of 57.3x. Average trailing P/E is 33x in the Healthcare Services industry in Asia. Total returns to shareholders of 37% over the past three years.
Reported Earnings • Aug 13Second quarter 2025 earnings released: EPS: LK₨0.05 (vs LK₨0.04 in 2Q 2024)Second quarter 2025 results: EPS: LK₨0.05 (up from LK₨0.04 in 2Q 2024). Revenue: LK₨66.2m (up 11% from 2Q 2024). Net income: LK₨6.70m (up 22% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (27% accrual ratio). Revenue is less than US$1m (LK₨258m revenue, or US$858k). Market cap is less than US$10m (LK₨1.71b market cap, or US$5.69m). Minor Risk Share price has been volatile over the past 3 months (6.4% average weekly change).
お知らせ • Jun 02eChannelling PLC, Annual General Meeting, Jun 26, 2025eChannelling PLC, Annual General Meeting, Jun 26, 2025, at 12:30 Sri Lanka Standard Time. Location: new wing hall, sri lanka foundation institute, no.100, sri lanka padanam mawatha, independence, square, colombo 07, colombo Sri Lanka
Reported Earnings • May 09First quarter 2025 earnings released: EPS: LK₨0.09 (vs LK₨0.09 in 1Q 2024)First quarter 2025 results: EPS: LK₨0.09 (in line with 1Q 2024). Revenue: LK₨66.9m (up 3.0% from 1Q 2024). Net income: LK₨11.4m (up 9.3% from 1Q 2024). Profit margin: 17% (up from 16% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
Board Change • Apr 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non Executive Director T.M.Ruwanthi Perera was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 01Full year 2024 earnings released: EPS: LK₨0.26 (vs LK₨0.36 in FY 2023)Full year 2024 results: EPS: LK₨0.26 (down from LK₨0.36 in FY 2023). Revenue: LK₨255.9m (down 5.6% from FY 2023). Net income: LK₨31.9m (down 27% from FY 2023). Profit margin: 13% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
お知らせ • Feb 08eChannelling PLC Appoints Suneth Haputhanthri as Independent, Non-Executive DirectoreChannelling PLC announced the appointment of Mr. Suneth Haputhanthri as independent, non-executive director. Effective date is 7 February 2025.
Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: LK₨0.05 (vs LK₨0.09 in 3Q 2023)Third quarter 2024 results: EPS: LK₨0.05 (down from LK₨0.09 in 3Q 2023). Revenue: LK₨65.1m (down 5.4% from 3Q 2023). Net income: LK₨5.69m (down 50% from 3Q 2023). Profit margin: 8.7% (down from 17% in 3Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to LK₨15.00, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 28x in the Healthcare Services industry in Asia. Total returns to shareholders of 76% over the past three years.
Buy Or Sell Opportunity • Oct 14Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 3.0% to LK₨13.70. The fair value is estimated to be LK₨11.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 6.2%.
Buy Or Sell Opportunity • Sep 26Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 3.7% to LK₨14.00. The fair value is estimated to be LK₨11.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 6.2%.
Reported Earnings • Jul 30Second quarter 2024 earnings released: EPS: LK₨0.04 (vs LK₨0.08 in 2Q 2023)Second quarter 2024 results: EPS: LK₨0.04 (down from LK₨0.08 in 2Q 2023). Revenue: LK₨59.8m (down 6.3% from 2Q 2023). Net income: LK₨5.49m (down 46% from 2Q 2023). Profit margin: 9.2% (down from 16% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.
Reported Earnings • May 17First quarter 2024 earnings released: EPS: LK₨0.09 (vs LK₨0.082 in 1Q 2023)First quarter 2024 results: EPS: LK₨0.09 (up from LK₨0.082 in 1Q 2023). Revenue: LK₨65.0m (down 2.0% from 1Q 2023). Net income: LK₨10.4m (flat on 1Q 2023). Profit margin: 16% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.
お知らせ • Apr 21eChannelling PLC, Annual General Meeting, May 14, 2024eChannelling PLC, Annual General Meeting, May 14, 2024, at 12:30 Sri Lanka Standard Time. Location: "Ruby",Bandaranaike Memorial International Conference Hall (BMICH) Bauddhaloka Mawatha Colombo Sri Lanka Agenda: To consider the Statement of Accounts of the company for the year ended 31 December 2023; to consider election of directors; to consider reappointment of Messrs KPMG, Chartered Accountants as auditors and to determine their remuneration; to authorize the Directors to determine their remuneration; and to consider other business matters.
Reported Earnings • Mar 03Full year 2023 earnings released: EPS: LK₨0.36 (vs LK₨0.54 in FY 2022)Full year 2023 results: EPS: LK₨0.36 (down from LK₨0.54 in FY 2022). Revenue: LK₨271.2m (up 22% from FY 2022). Net income: LK₨43.8m (down 33% from FY 2022). Profit margin: 16% (down from 30% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 16Third quarter 2023 earnings released: EPS: LK₨0.09 (vs LK₨0.13 in 3Q 2022)Third quarter 2023 results: EPS: LK₨0.09 (down from LK₨0.13 in 3Q 2022). Revenue: LK₨68.7m (up 43% from 3Q 2022). Net income: LK₨11.4m (down 27% from 3Q 2022). Profit margin: 17% (down from 33% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to LK₨16.50, the stock trades at a trailing P/E ratio of 36.3x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 123% over the past three years.
Reported Earnings • Aug 05Second quarter 2023 earnings released: EPS: LK₨0.08 (vs LK₨0.09 in 2Q 2022)Second quarter 2023 results: EPS: LK₨0.08 (down from LK₨0.09 in 2Q 2022). Revenue: LK₨63.9m (up 47% from 2Q 2022). Net income: LK₨10.2m (down 11% from 2Q 2022). Profit margin: 16% (down from 26% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to LK₨16.80, the stock trades at a trailing P/E ratio of 37x. Average trailing P/E is 36x in the Healthcare Services industry in Asia. Total returns to shareholders of 265% over the past three years.
Reported Earnings • Apr 22Full year 2022 earnings released: EPS: LK₨0.54 (vs LK₨0.44 in FY 2021)Full year 2022 results: EPS: LK₨0.54 (up from LK₨0.44 in FY 2021). Revenue: LK₨221.5m (up 15% from FY 2021). Net income: LK₨65.5m (up 23% from FY 2021). Profit margin: 30% (up from 28% in FY 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 19%After last week's 19% share price gain to LK₨18.80, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 43x in the Healthcare Services industry in Asia. Total returns to shareholders of 437% over the past three years.
Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to LK₨14.00, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 40x in the Healthcare Services industry in Asia. Total returns to shareholders of 300% over the past three years.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Independent Non Executive Chairman Anthony Rohan Fernando was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 23% share price gain to LK₨13.80, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 151% over the past three years.
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improved over the past weekAfter last week's 17% share price gain to LK₨11.60, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 40x in the Healthcare Services industry in Asia. Total returns to shareholders of 111% over the past three years.
Reported Earnings • Nov 11Third quarter 2022 earnings released: EPS: LK₨0.13 (vs LK₨0.13 in 3Q 2021)Third quarter 2022 results: EPS: LK₨0.13 (in line with 3Q 2021). Revenue: LK₨48.0m (up 2.5% from 3Q 2021). Net income: LK₨15.7m (down 4.0% from 3Q 2021). Profit margin: 33% (down from 35% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improved over the past weekAfter last week's 24% share price gain to LK₨11.20, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 35x in the Healthcare Services industry in Asia. Total returns to shareholders of 115% over the past three years.
Reported Earnings • Aug 09Second quarter 2022 earnings released: EPS: LK₨0.09 (vs LK₨0.06 in 2Q 2021)Second quarter 2022 results: EPS: LK₨0.09 (up from LK₨0.06 in 2Q 2021). Revenue: LK₨43.4m (up 18% from 2Q 2021). Net income: LK₨11.4m (up 65% from 2Q 2021). Profit margin: 26% (up from 19% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 21% share price gain to LK₨8.70, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 43x in the Healthcare Services industry in Asia. Total returns to shareholders of 71% over the past three years.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improved over the past weekAfter last week's 19% share price gain to LK₨6.90, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 41x in the Healthcare Services industry in Asia. Total returns to shareholders of 47% over the past three years.
Valuation Update With 7 Day Price Move • May 30Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to LK₨7.00, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 36x in the Healthcare Services industry in Asia. Total returns to shareholders of 133% over the past three years.
Reported Earnings • May 16First quarter 2022 earnings released: EPS: LK₨0.16 (vs LK₨0.16 in 1Q 2021)First quarter 2022 results: EPS: LK₨0.16 (vs LK₨0.16 in 1Q 2021). Revenue: LK₨59.5m (up 17% from 1Q 2021). Net income: LK₨19.2m (down 1.5% from 1Q 2021). Profit margin: 32% (down from 38% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorated over the past weekAfter last week's 27% share price decline to LK₨7.50, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 41x in the Healthcare Services industry in Asia. Total returns to shareholders of 74% over the past three years.
Buying Opportunity • Mar 29Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 71%. The fair value is estimated to be LK₨10.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% per annum over the last 3 years. Earnings per share has grown by 29% per annum over the last 3 years.
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to LK₨10.30, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 158% over the past three years.
Reported Earnings • Mar 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: LK₨0.44 (up from LK₨0.25 in FY 2020). Revenue: LK₨193.2m (up 49% from FY 2020). Net income: LK₨53.4m (up 78% from FY 2020). Profit margin: 28% (up from 23% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to LK₨12.40, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 37x in the Healthcare Services industry in Asia. Total returns to shareholders of 202% over the past three years.
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to LK₨17.10, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 42x in the Healthcare Services industry in Asia. Total returns to shareholders of 307% over the past three years.
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to LK₨22.60, the stock trades at a trailing P/E ratio of 52.1x. Average trailing P/E is 49x in the Healthcare Services industry in Asia. Total returns to shareholders of 381% over the past three years.
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 23% share price gain to LK₨21.30, the stock trades at a trailing P/E ratio of 49.1x. Average trailing P/E is 52x in the Healthcare Services industry in Asia. Total returns to shareholders of 384% over the past three years.
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to LK₨11.20, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 44x in the Healthcare Services industry in Asia. Total returns to shareholders of 149% over the past three years.
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS LK₨0.13 (vs LK₨0.11 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: LK₨46.8m (up 17% from 3Q 2020). Net income: LK₨16.4m (up 19% from 3Q 2020). Profit margin: 35% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Sep 02Investor sentiment improved over the past weekAfter last week's 24% share price gain to LK₨8.40, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 53x in the Healthcare Services industry in Asia. Total returns to shareholders of 79% over the past three years.
Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS LK₨0.06 (vs LK₨0.02 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: LK₨36.7m (up 60% from 2Q 2020). Net income: LK₨6.90m (up 144% from 2Q 2020). Profit margin: 19% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to LK₨7.00, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 55x in the Healthcare Services industry in Asia. Total returns to shareholders of 49% over the past three years.
Reported Earnings • May 17First quarter 2021 earnings released: EPS LK₨0.16 (vs LK₨0.03 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: LK₨50.8m (up 56% from 1Q 2020). Net income: LK₨19.5m (up LK₨16.4m from 1Q 2020). Profit margin: 38% (up from 9.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 25New 90-day low: LK₨5.80The company is down 15% from its price of LK₨6.80 on 27 November 2020. The Sri Lankan market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 7.0% over the same period.
Reported Earnings • Feb 25Full year 2020 earnings released: EPS LK₨0.25 (vs LK₨0.12 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: LK₨130.1m (flat on FY 2019). Net income: LK₨30.0m (up 100% from FY 2019). Profit margin: 23% (up from 12% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 02New 90-day low: LK₨6.10The company is down 14% from its price of LK₨7.10 on 04 November 2020. The Sri Lankan market is up 49% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 16% over the same period.
Reported Earnings • Nov 04Third quarter 2020 earnings released: EPS LK₨0.11The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: LK₨40.1m (up 26% from 3Q 2019). Net income: LK₨13.7m (up 244% from 3Q 2019). Profit margin: 34% (up from 13% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Sep 24New 90-day high: LK₨6.00The company is up 40% from its price of LK₨4.30 on 26 June 2020. The Sri Lankan market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 6.0% over the same period.